Showing 2681-2690 of 10620 results for "".
How Anti-VEGF Compares with Steroids in Retinal Vein Occlusion
https://reachmd.com/programs/eye-on-ocular-health/anti-vegf-vs-steroids-retinal-vein-occlusion/54483/Macular edema remains a leading cause of vision loss in retinal vein occlusion—but which therapy truly delivers the best balance of benefit and risk? In this AudioAbstract, Ryan Quigley discusses a January 2026 Frontiers in Medicine meta-analysis comparing anti-VEGF monotherapy, steroid monotherapyGender Bias and Heart Health: Improving Cardiovascular Care for Women
https://reachmd.com/programs/heart-matters/gender-bias-and-heart-health-improving-cardiovascular-care-for-women/37856/Cardiovascular disease is the leading cause of mortality in women, yet it is often underrecognized due to gender bias in healthcare. Hear from Dr. Connie Newman as she explores the impact of bias on cardiovascular risk perception, highlights the importance of lipid and Lp(a) screening, and reviews eSjögren’s Disease Management: A Decade in Review
https://reachmd.com/programs/living-rheum/sjogrens-disease-management-a-decade-in-review/36342/Key Advances in Rheumatology at CCR East 2026
https://reachmd.com/programs/living-rheum/rheumatology-advances-ccr-east-2026/54373/From early arthritis treatment pathways to emerging digital health tools, the 2026 Congress of Clinical Rheumatology East conference spotlights the clinical and scientific advances shaping the future of rheumatology care. Joining us to outline those key themes and sessions is Dr. Louis Bessette, ProHow Delayed Colorectal Cancer Screening Impacts Quality of Life
https://reachmd.com/programs/clinicians-roundtable/delayed-colorectal-cancer-screening-quality-of-life/56448/Delayed colorectal cancer screening can significantly impact not only clinical outcomes, but also patients’ long-term quality of life. Tune in to hear Dr. Christopher Cann share his insights on these lasting consequences, including the need for more extensive surgery and systemic therapies, the burdAdvances in DMD Care: Evaluating a Gene Therapy’s Efficacy and Safety
https://reachmd.com/programs/neurofrontiers/advances-in-dmd-care-evaluating-a-gene-therapys-efficacy-and-safety/26327/Explore the efficacy and safety data that led to the expanded approval of a gene therapy for patients with Duchenne muscular dystrophy.Mind Matters: Psychiatric Comorbidity in the Prodromal Phase of MS
https://reachmd.com/programs/neurofrontiers/mind-matters-psychiatric-comorbidity-in-the-prodromal-phase-of-ms/16269/A recent study investigated if psychiatric conditions can be an early predictor of MS. Let's dive into the findings.Addressing the Hidden Burden of Negative Symptoms in Schizophrenia
https://reachmd.com/programs/neurofrontiers/negative-symptoms-in-schizophrenia/39940/Negative symptoms of schizophrenia—such as emotional flatness, social withdrawal, and lack of motivation—are often subtle, persistent, and underrecognized, yet they significantly impact patient functioning and quality of life. To learn more about this hidden burden, Dr. Alexandria May speaks with DrAnti-OX40 Ligand Antibody Trials
https://reachmd.com/series/updates-atopic-dermatitis/anti-ox40-ligand-antibody-trials/29531/Lead study author Stephan Weidinger, MD, PhD, Director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, discusses the phase 2b STREAM-AD trial, evaluating amlitelimab in adult patients with moderate-to-severe atopic dermatitis.Psychoneuroimmunology
https://reachmd.com/programs/clinicians-roundtable/psychoneuroimmunology-1/861/Join Patty Wooten, past President of the American Association for Therapeutic Humor, and a leading national expert in the field of therapeutic humor, discuss how what we think and feel affects our physical health.